Episode Details

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, before discussing viral transmission to adults in healthcare setting, the recently EUA approved protein based COBREVAX vaccine, reviews quarantine guidelines, the use of simnotrelivr for mild to moderate COVID-19, how viral RNA may persist in your cell culture dish following antiviral therapy, continues to dispel the myth of viral rebound, how to pay for Paxlovid, , when to use steroids and the benefits of convalescent plasma, how Paxlovid may prevent long COVID and how complement dysfunction may lead to thromboinflammation during long COVID.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Articles and graphs cited in TWIV CU 1080
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Variant hospital admissions (CDC)
• Transmission in healthcare setting (CID)
• COBREVAX EUA (Texas Children’s Hospital)
• Quarantine/isolation guidelines (CDC)
• Simnotrelvir for mild to moderate disease in adults (NEJM)
• Are your tissue culture cells persistently infected following antiviral therapy (bioRxiv)
• Structural biology of antivirals for SARS-CoV-2 (Signal Tranduction and Targeted Therapy)
• To rebound or to 

  Listen Now